RBC Capital Maintains Applied Therapeutics(APLT.US) With Buy Rating, Maintains Target Price $12

RBC Capital analyst Brian Abrahams maintains $Applied Therapeutics(APLT.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 51.1

Moomoo NewsJul 17 12:38 ET · Ratings

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)

TipRanksJul 17 12:02 ET

Express News | RBC Capital Reiterates Outperform on Applied Therapeutics, Maintains $12 Price Target

BenzingaJul 17 10:00 ET

Applied Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/17/2024 117.79% RBC Capital $12 → $12 Reiterates Outperform → Outperform 04/11/2024 117.79% RBC

BenzingaJul 17 09:59 ET

CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 40 points on Tuesday.Shares of CrossFirst Bankshares, Inc. (NASDAQ:CFB) fell sharply in today's pre-market trading

BenzingaJul 16 08:15 ET

Express News | Applied Therapeutics Was Added To The Russell 3000 Index, Effective After The U.S. Market Closed On June 28, 2024, As Part Of The 2024 Russell Indexes Annual Reconstitution

BenzingaJul 1 07:09 ET